Benefits
Less bloating and gas
In a 12-week placebo-controlled trial in 108 analyzed adults with IBS, 6 g a day of Sunfiber lowered bloating and bloating-plus-gas journal scores, and the effect lasted 4 weeks after stopping. It did not change abdominal pain, stool frequency, overall IBS severity or quality of life.
Better tolerated than wheat bran as a fiber source
In a 12-week open-label trial in 188 adults with IBS, 5 g a day of PHGG and 30 g a day of wheat bran both improved pain and bowel habits, with no difference per protocol. More people switched from bran to PHGG than the reverse, and success by intention to treat was 60% versus 40%.
More normal stool form in adults with loose stools
In a 12-week placebo-controlled trial in 44 healthy Japanese adults with loose-stool tendencies, 5 g a day of Sunfiber moved stool form toward normal, with significant differences from placebo at some weeks. Stool frequency did not change. The maker funded the trial.
Bowel regularity in children
In a 4-week randomized trial in 61 children with chronic functional constipation, weekly bowel movements rose from about 4 to 5 with PHGG and from about 4 to 6 with lactulose, and stool consistency improved in both groups. Parents reported more bad taste and gas with lactulose. The trial was not designed to show the two were equal.
Fewer diarrhea days with tube feeding
In 25 tube-fed ICU patients with severe sepsis, a formula with 22 g of PHGG per liter cut the share of feeding days with diarrhea from 32% to 8.8% compared with a fiber-free formula. It did not change deaths or length of ICU stay. This is hospital nutrition under medical care, not everyday use.
Blood sugar markers in one 6-week trial
In 44 adults with type 2 diabetes and metabolic syndrome, adding 10 g a day of PHGG to the usual diet lowered HbA1c (6.88% to 6.57%) and waist size from baseline over 6 weeks, while the control group showed no such change. Fasting glucose did not change. This is one small trial in people under diabetes care.
Cholesterol: no change in the cited trial
In the same 44-person trial, total and LDL cholesterol did not change in either group. None of the trials on this page shows a cholesterol benefit for PHGG.
Shifts in gut bacteria and short-chain fatty acids
With 5 g a day of Sunfiber for 12 weeks, stool Bifidobacterium rose and Bacteroides fell versus placebo. In a 20-person study of another PHGG at 5 to 15 g a day, stool butyrate and acetate rose, species richness did not change and evenness fell, and most changes faded after stopping.
Mechanism of action
Enzyme-shortened guar fiber
Sunfiber is made by treating guar gum with an endo-galactomannanase enzyme from Aspergillus niger. The shorter chains give a water-soluble, non-gelling fiber without the thick gel of native guar gum, so it can be stirred into drinks.
Fermented by colon bacteria
PHGG reaches the colon, where bacteria ferment it. In a 20-person study, PHGG raised stool butyrate and acetate, short-chain fatty acids made by gut bacteria, and most of the changes seen in that study faded after it was stopped.
Changes in stool bacteria
In a placebo-controlled trial, Sunfiber raised stool Bifidobacterium, Ruminococcus and Megasphaera and lowered Bacteroides. The authors linked these shifts to the change in stool form, but the trial cannot show cause and effect.
Clinical trials
Multicenter, randomized, open-label trial comparing PHGG 5 g/day to wheat bran 30 g/day for 12 weeks, measuring abdominal pain, bowel habits, and overall subjective rating, with the option to switch groups after 4 weeks (Parisi et al. 2002, Dig Dis Sci).
188 adult IBS patients (139 women, 49 men) across multiple Italian gastroenterology centers.
Both fibers improved pain and bowel habits, with no difference between groups per protocol. By intention to treat, PHGG had greater success (60% vs 40%) and was better tolerated: 49.9% switched from wheat bran to PHGG at week 4 versus 10.9% the other way. The trial was not blinded.
Double-blind placebo-controlled RCT spanning 18 weeks (2-wk run-in, 12-wk treatment, 4-wk follow-up) of Sunfiber PHGG (3 g/day for the first week, then 6 g/day) vs maltodextrin placebo, with daily symptom journals (Niv et al. 2016, Nutr Metab (Lond)).
121 IBS patients randomized (108 analyzed: 49 PHGG, 59 placebo) in Israel.
PHGG improved journal bloating scores and combined bloating-and-gas scores vs placebo, with benefits persisting 4 weeks after stopping. It had no effect on abdominal pain, stool frequency, overall severity or quality of life. Dropout was lower on PHGG (22% vs 49%).
Randomized controlled trial comparing PHGG (31 children) to lactulose (30 children) over 4 weeks, measuring weekly defecation frequency, stool consistency, and family-reported tolerability (Üstündağ et al. 2010, Turk J Gastroenterol).
61 children with chronic functional constipation at a Turkish pediatric gastroenterology clinic.
Bowel frequency and stool consistency improved in both groups. Weekly bowel movements rose from about 4 to 5 with PHGG and from about 4 to 6 with lactulose. Parents reported bad taste and gas with lactulose, while families using PHGG were satisfied with bowel frequency. The trial was not designed to test equivalence.
Randomized, double-blind, placebo-controlled, parallel-group trial of Sunfiber PHGG 5 g/day vs maltodextrin placebo for 12 weeks plus a 4-week washout, with stool diaries and 16S microbiota sequencing; funded by the maker (Yasukawa et al. 2019, Nutrients).
44 healthy Japanese adults (mean age 41.9) with loose-stool tendencies, 22 per group.
PHGG moved Bristol stool scores toward normal versus placebo, with significant differences at weeks 7 and 11. Stool Bifidobacterium rose and Bacteroides fell relative to placebo. Stool frequency and the physical quality-of-life score did not differ between groups.
Prospective, double-blind, randomized controlled trial comparing enteral formula with 22 g/L PHGG vs isocaloric, isonitrogenous fiber-free formula for at least 6 days via nasogastric tube (Spapen et al. 2001, Clin Nutr).
25 ICU patients with severe sepsis or septic shock (13 PHGG, 12 control) at a Belgian academic hospital.
Mean percentage of days with diarrhea was 8.8% in the PHGG group vs 32.0% in the fiber-free control group (p=0.001). No effect on sepsis mortality or ICU length of stay.